Pfizer Inc: Form 10-Q for the period ended Jul 4, 2021
Filed with the SEC on Aug 12, 2021 and accepted by EDGAR at Aug 12, 2021, 16:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-07-04. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-04-05 to 2021-07-04 | $18.98bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2021-01-01 to 2021-07-04 | $33.56bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2021-04-05 to 2021-07-04 | $7.05bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2021-01-01 to 2021-07-04 | $11.26bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months2021-04-05 to 2021-07-04 | $2.93bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2021-01-01 to 2021-07-04 | $5.71bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months2021-04-05 to 2021-07-04 | $316.0m | us-gaap:InterestExpense |
| Interest expense | 6 months2021-01-01 to 2021-07-04 | $651.0m | us-gaap:InterestExpense |
| Income tax | 3 months2021-04-05 to 2021-07-04 | $1.04bn | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2021-01-01 to 2021-07-04 | $1.85bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-04-05 to 2021-07-04 | $5.56bn | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-07-04 | $10.44bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-04-05 to 2021-07-04 | $0.98 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2021-01-01 to 2021-07-04 | $1.84 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-04-05 to 2021-07-04 | $0.99 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2021-01-01 to 2021-07-04 | $1.87 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-04-05 to 2021-07-04 | 5,678,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2021-01-01 to 2021-07-04 | 5,670,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2021-01-01 to 2021-07-04 | $15.84bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2021-01-01 to 2021-07-04 | $1.09bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-07-04 | $2.37bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-07-04 | $48.81bn | us-gaap:AssetsCurrent |
| Total assets | At period end2021-07-04 | $169.92bn | us-gaap:Assets |
| Current liabilities | At period end2021-07-04 | $35.66bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-07-04 | $99.61bn | us-gaap:Liabilities |
| Long-term debt | At period end2021-07-04 | $35.35bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2021-07-04 | $3.69bn | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2021-07-04 | $100.0m | us-gaap:CommercialPaper |
| Shareholders' equity | At period end2021-07-04 | $70.04bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000078003-21-000093. Last ingested by Listed: Nov 12, 2026, 18:08 ET. Listed shows no prices and gives no investment advice.